GENUI and SHS Capital Invest in ROTOP's Radiopharmaceutical Expansion

Healthcare investors GENUI and SHS Capital have jointly invested in ROTOP Pharmaka GmbH, a prominent German company specializing in radiopharmaceuticals. This strategic cooperation aims to expand ROTOP's production capabilities to cater to the rising demand for radiopharmaceutical products used in diagnostics and therapy, particularly in nuclear medicine.

ROTOP, founded in 2000, is recognized for its innovation in radiopharmaceuticals, products crucial for cancer imaging and treatment due to their ability to target diseases while minimizing harm to healthy tissues. The radiopharmaceutical market has experienced substantial growth recently, outpacing traditional biotech sectors, driven by the sector's medical and economic success.

With the support of GENUI and SHS, ROTOP plans to significantly increase its capacities for contract development and manufacturing operations (CDMO), focusing on radio-ligand therapy. The investment aligns with ROTOP's ongoing expansion plan to meet market needs efficiently.